By Kyle Morris

AstraZeneca PLC said Tuesday that Forxiga has been approved in the European Union for the treatment of symptomatic chronic heart failure.

The Anglo-Swedish pharma giant said the approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use in December 2022 and was based on results from the Deliver Phase 3 trial.

Heart failure is a chronic, long-term condition that worsens over time and affects about 15 million people in Europe, the company said.

Write to Kyle Morris at kyle.morris@dowjones.com

(END) Dow Jones Newswires

February 07, 2023 02:36 ET (07:36 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
過去 株価チャート
から 3 2024 まで 4 2024 Astrazenecaのチャートをもっと見るにはこちらをクリック
Astrazeneca (LSE:AZN)
過去 株価チャート
から 4 2023 まで 4 2024 Astrazenecaのチャートをもっと見るにはこちらをクリック